CHICAGO (GenomeWeb) – Baptist Health South Florida has tapped healthcare data and analytics company Cota to help build precision medicine and research programs at the year-old Miami Cancer Institute.
New York-based Cota said today that the Miami Cancer Institute will use Cota's oncology analytics suite to identify clinical variances, provide clinical decision support, and optimize billing in both fee-for-service and value-based payment models. This suite includes the Cota Nodal Address patient classification system as well as Cota Real-World Evidence, an oncology knowledge base.
"With the ability to see genomic-level data alongside cost and historical clinical data, Cota will help accelerate our journey to value-based care," Leonard Kalman, executive deputy director and chief medical officer of Miami Cancer Institute, said in a statement. "This not only increases the level of precision in our patients' treatment journey, but it also ensures that every individual receives the highest quality of care possible which increases the odds of survivorship."
Miami Cancer Institute, which opened in January 2017, is a member of the Memorial Sloan Kettering Cancer Center Alliance. In November, MSK announced a multiyear partnership with Cota in which the vendor will build clinical and genomic data sets on behalf of the New York institution in an effort to improve patient care and research.